{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:36:56Z","timestamp":1793871416192,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001505","name":"The Health Research Council of New Zealand","doi-asserted-by":"crossref","award":["18\/151"],"award-info":[{"award-number":["18\/151"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1136\/ard-2023-224731","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T13:20:13Z","timestamp":1693488013000},"page":"1626-1634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-2912","authenticated-orcid":false,"given":"Lisa","family":"Stamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borislav","family":"Mihov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Haslett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-4476","authenticated-orcid":false,"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224731_bib1","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/S2665-9913(21)00319-2","article-title":"Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials","volume":"4","author":"Stamp","year":"2022","journal-title":"Lancet Rheumatology"},{"key":"10.1136\/ard-2023-224731_bib2","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricaemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224731_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1136\/ard-2023-224731_bib4","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricaemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224731_bib5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"American college of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224731_bib6","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/rheumatology\/kex250","article-title":"The British society for rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224731_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"Updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224731_bib8","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome. A proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224731_bib9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"American college of rheumatology guidelines for the management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2023-224731_bib10","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224731_bib11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224731_bib12","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"Gout classification criteria an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224731_bib13","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricaemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224731_bib14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1136\/ard-2023-224731_bib15","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials","volume":"32","author":"Wortmann","year":"2010","journal-title":"Clin Ther"},{"key":"10.1136\/ard-2023-224731_bib16","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224731_bib17","series-title":"Evidence reviews for colchicine, NSAIDs, corticosteroids and IL-1 inhibitors for the prevention of gout flares during the initiation or titration of urate-lowering therapy: gout: diagnosis and management: evidence review H, Copyright \u00a9 NICE 2022","author":"NICE Evidence Reviews Collection","year":"2022"},{"key":"10.1136\/ard-2023-224731_bib18","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"American college of rheumatology guidelines for the management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2023-224731_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2019-215315","article-title":"Updated European league against rheumatism evidence-based recommendations for the diagnosis of gout","volume":"79","author":"Richette","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224731_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease","volume":"135","author":"Robinson","year":"2022","journal-title":"Am J Med"},{"key":"10.1136\/ard-2023-224731_bib21","first-page":"61","article-title":"Colchicine in cardiovascular disease: in-depth review","volume":"145","author":"Deftereos","year":"2022","journal-title":"Circulation"},{"key":"10.1136\/ard-2023-224731_bib22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.semarthrit.2019.11.002","article-title":"How flare prevention outcomes are reported in gout studies: a systematic review and content analysis of randomized controlled trials","volume":"50","author":"Stewart","year":"2020","journal-title":"Semin Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T03:16:17Z","timestamp":1736046977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724083729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0003496724083729"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224731","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}